$CRNX News

Here's How Much $1000 Invested In Crinetics Pharmaceuticals 5 Years Ago Would Be Worth Today

TD Cowen Downgrades Crinetics Pharmaceuticals to Hold

Evercore ISI Group Downgrades Crinetics Pharmaceuticals to In-Line, Lowers Price Target to $85

Oppenheimer Downgrades Crinetics Pharmaceuticals to Perform

Cantor Fitzgerald Downgrades Crinetics Pharmaceuticals to Neutral

HC Wainwright & Co. Downgrades Crinetics Pharmaceuticals to Neutral, Raises Price Target to $85

Baird Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $85

UBS Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $55

Crinetics Pharmaceuticals: 'Buy' On Palsonify Market Expansion And Atumelnant Advancements

Leerink Upholds Outperform Rating for Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals, Inc. (CRNX) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - Slideshow

HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price Target

Reported Sunday, Crinetics Presents Up To Two-Year PATHFNDR Open-Label Extension Data At ENDO 2026 Confirming PALSONIFY Maintains Stable IGF-1 Levels And Acromegaly Symptom Control

Reported Sunday, Crinetics Presents Phase 2 Data For Atumelnant In CAH Showing 67% Mean Reduction In Androstenedione Levels With 88% Of Participants Achieving Physiologic Glucocorticoid Dose At Week 12

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Citizens Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $95 Price Target

Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why

A Look At Crinetics Pharmaceuticals (CRNX) Valuation As New Endocrine Data Heads To ENDO 2026

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities